Condition
Rosai-Dorfman Disease
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 2 (2)
P 4 (1)
Trial Status
Unknown2
Recruiting2
Clinical Trials (4)
Showing 4 of 4 trials
NCT05093335Early Phase 1Recruiting
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
NCT07187167Phase 2RecruitingPrimary
Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease
NCT05284942Phase 4UnknownPrimary
Central China Rosai-Dorfman Disease Registry
NCT04924647Phase 2UnknownPrimary
Lenalidomide and Dexamethasone for Rosai-Dorfman Disease
Showing all 4 trials